Table 4 Disease severity in ENVISION trial participants according to hemin prophylaxis at baseline
From: Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study
| Â | No prior hemin prophylaxis | Prior hemin prophylaxis | ||
|---|---|---|---|---|
Placebo (n = 28) | Givosiran (n = 28) | Placebo (n = 18) | Givosiran (n = 20) | |
Historical AAR, median (range) | 6.0 (0–46) | 8.0 (4–34) | 9.0 (4–38) | 9.0 (4–32) |
Chronic symptoms, n (%) | 17 (61) | 16 (57) | 9 (50) | 7 (35) |
Chronic opioid use, n (%) | 7 (25) | 6 (21) | 6 (33) | 8 (40) |
EQ VAS, mean (SD) | 63.9 (20.7) | 58.4 (23.0) | 64.8 (18.4) | 68.4 (21.3) |
SF-12 PCS, mean (SD) | 36.5 (10.5)a | 39.3 (11.2) | 40.5 (8.4) | 39.7 (7.8) |